NICE Technology Appraisal guidance (TA875 for semaglutide/Wegovy and TA664 for liraglutide/Saxenda) recommends these medications for weight management in adults with: A body mass index (BMI) of at least 35 kg/m and At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or non-alcoholic fatty liver disease) For liraglutide (Saxenda), NICE TA664 specifies additional criteria including prediabetes (HbA1c 42-47 mmol/mol or fasting plasma glucose 5.5-6.9 mmol/L) or high risk of cardiovascular disease
Exosomes: proteomic insights and diagnostic potential
Understanding the components, common uses, and variations in needle gauge and length is essential for effective diabetes management
Known as the lunchtime facial, this 1064 nm Nd:YAG treatment softens the appearance of fine lines, improves uneven texture, and reduces redness, flushing, pigmented lesions, and acne scarsconcerns that can become more visible as facial volume shifts during weight loss
Inhibitory means that it helps to slow down excessive brain activity by turning off certain excitatory receptors
Fisher and his team can help you achieve sustainable, long-term results